Scynexis (SCYX) EBIT Margin Growth (1y) (2014 - 2026)
Analysis
Scynexis (SCYX) EBIT Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,881.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.23 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -260,756.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -260,756.00 |
| Dec 31, 2025 | 88,068.00 |
| Sep 30, 2025 | -95,283.00 |
| Jun 30, 2025 | 55,407.00 |
| Mar 31, 2025 | -265,770.00 |
| Dec 31, 2024 | -42,638.00 |
| Sep 30, 2024 | -99,021.00 |
| Jun 30, 2024 | -134,366.00 |
| Mar 31, 2024 | 25,281.00 |
| Dec 31, 2023 | 107,725.00 |
| Sep 30, 2023 | 82,677.00 |
| Jun 30, 2023 | 173,172.00 |
| Mar 31, 2023 | 187,440.00 |
| Dec 31, 2022 | 225,971.00 |
| Sep 30, 2022 | 236,744.00 |
| Mar 31, 2022 | -280,649.00 |
| Jun 30, 2019 | -767,648.00 |
| Mar 31, 2019 | -723,125.00 |
| Dec 31, 2018 | -254,531.00 |
| Sep 30, 2018 | 15,156.00 |